IL123654A - Process for the preparation of solid mixtures of cyclodextrins and pharmaceutical preparations containing such solid mixtures - Google Patents

Process for the preparation of solid mixtures of cyclodextrins and pharmaceutical preparations containing such solid mixtures

Info

Publication number
IL123654A
IL123654A IL12365496A IL12365496A IL123654A IL 123654 A IL123654 A IL 123654A IL 12365496 A IL12365496 A IL 12365496A IL 12365496 A IL12365496 A IL 12365496A IL 123654 A IL123654 A IL 123654A
Authority
IL
Israel
Prior art keywords
mixture
cyclodextrins
melt
cyclodextrin
solid mixture
Prior art date
Application number
IL12365496A
Other languages
English (en)
Hebrew (he)
Other versions
IL123654A0 (en
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26139823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL123654(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL123654A0 publication Critical patent/IL123654A0/xx
Publication of IL123654A publication Critical patent/IL123654A/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL12365496A 1995-11-23 1996-11-20 Process for the preparation of solid mixtures of cyclodextrins and pharmaceutical preparations containing such solid mixtures IL123654A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP95203219 1995-11-23
PCT/EP1996/005118 WO1997018839A1 (fr) 1995-11-23 1996-11-20 Melanges solides de cyclodextrines prepares par fusion-extrusion
US09/081,808 US6365188B1 (en) 1995-11-23 1998-05-20 Solid mixtures of cyclodextrins prepared via meltextrusion

Publications (2)

Publication Number Publication Date
IL123654A0 IL123654A0 (en) 1998-10-30
IL123654A true IL123654A (en) 2001-08-08

Family

ID=26139823

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12365496A IL123654A (en) 1995-11-23 1996-11-20 Process for the preparation of solid mixtures of cyclodextrins and pharmaceutical preparations containing such solid mixtures

Country Status (16)

Country Link
US (1) US6365188B1 (fr)
EP (1) EP0862463A1 (fr)
JP (1) JP3310299B2 (fr)
CN (1) CN1198655C (fr)
AU (1) AU725204B2 (fr)
BR (1) BR9611562A (fr)
CZ (1) CZ154398A3 (fr)
HU (1) HUP9900730A3 (fr)
IL (1) IL123654A (fr)
NO (1) NO981078L (fr)
NZ (1) NZ322907A (fr)
PL (1) PL189122B1 (fr)
SK (1) SK67298A3 (fr)
TR (1) TR199800729T2 (fr)
WO (1) WO1997018839A1 (fr)
ZA (1) ZA969831B (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0862463A1 (fr) * 1995-11-23 1998-09-09 Janssen Pharmaceutica N.V. Melanges solides de cyclodextrines prepares par fusion-extrusion
KR19990001564A (ko) 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제
ATE214595T1 (de) * 1997-11-28 2002-04-15 Knoll Ag Verfahren zur herstellung von lösungsmittelfreien nicht-kristallinen biologisch aktiven substanzen
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
KR100658489B1 (ko) 1998-11-10 2006-12-18 얀센 파마슈티카 엔.브이. Ｈｉｖ 복제를 억제하는 피리미딘
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
DE19911097A1 (de) * 1999-03-12 2000-09-14 Basf Ag Verfahren zur Herstellung von festen cyclodextrinhaltigen Dosierungsformen
DE60023465T2 (de) 1999-03-24 2006-07-20 R.P. Scherer Technologies, Inc., Las Vegas Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser
EA200101172A1 (ru) 1999-05-04 2002-04-25 Янссен Фармацевтика Н.В. Противогрибковые эфиры
FR2803748A1 (fr) * 2000-01-14 2001-07-20 Ethypharm Lab Prod Ethiques Composition d'itraconazole et procede de preparation
AU2001237401B2 (en) 2000-03-01 2006-11-09 Janssen Pharmaceutica N.V. 2,4-disubstituted thiazolyl derivatives
US6835717B2 (en) 2000-03-08 2004-12-28 The Johns Hopkins University School Of Medicine β-cyclodextrin compositions, and use to prevent transmission of sexually transmitted diseases
CA2406562C (fr) 2000-05-08 2009-09-15 Janssen Pharmaceutica N.V. Pyrimidines et triazines inhibant la replication du vih
ITRN20000051A1 (it) 2000-12-22 2002-06-22 Ascor Chimici Srl Metodo e apparecchiatura per formare sferule composite contenenti principi attivi del tipo farmaceutico e/o integratori alimentari o cosmeti
GB0113841D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
KR100979988B1 (ko) 2001-08-13 2010-09-03 얀센 파마슈티카 엔.브이. 2-아미노-4,5-삼치환 티아졸릴 유도체
JP4725945B2 (ja) 2002-03-13 2011-07-13 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼの新規な阻害剤としてのスルホニルアミノ誘導体
PL212089B1 (pl) 2002-03-13 2012-08-31 Janssen Pharmaceutica Nv Związki heterocykliczne jako inhibitory deacetylazy histonowej, kompozycja farmaceutyczna je zawierająca, ich zastosowanie, sposób wytwarzania, sposób wykrywania lub identyfikacji HDAC oraz kompozycja
US7399856B2 (en) 2002-08-09 2008-07-15 Janssen Pharmaceutica N.V. Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-2pyrimidinyl]amino]benzonitrile
EA010379B1 (ru) 2003-02-07 2008-08-29 Янссен Фармацевтика Н.В. Ингибирующие вич 1,2,4-триазины
JP5602333B2 (ja) 2003-02-07 2014-10-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｈｉｖ感染の予防のためのピリミジン誘導体
CL2004000303A1 (es) 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
MXPA05010330A (es) * 2003-03-28 2006-05-31 Ivax Corp Formulaciones de cladribina para el mejor suministro oral y a traves de la mucosa.
PT1608344E (pt) * 2003-03-28 2010-09-02 Ares Trading Sa Formulações orais de cladribina
EA009734B1 (ru) 2003-09-25 2008-02-28 Янссен Фармацевтика Н.В. Производные пурина, ингибирующие репликацию вич
US20050118265A1 (en) * 2003-11-28 2005-06-02 Anandi Krishnan Antifungal oral dosage forms and the methods for preparation
BRPI0512676B8 (pt) 2004-07-28 2021-05-25 Janssen Pharmaceutica Nv derivados de indolil alquil amina substituídos como inibidores de histona desacetilase, composição farmacêutica que os compreende, seus processos de preparação e uso
AU2005271161B2 (en) 2004-08-10 2011-05-12 Janssen Pharmaceutica N.V. HIV inhibiting 1,2,4-triazin-6-one derivatives
RU2410379C2 (ru) 2004-09-30 2011-01-27 Тиботек Фармасьютикалз Лтд. 5-замещенные пиримидины, ингибирующие вич
RU2405778C2 (ru) 2004-09-30 2010-12-10 Тиботек Фармасьютикалз Лтд. 5-гетероциклилпиримидины, ингибирующие вич
MX2007005159A (es) 2004-10-29 2007-06-26 Tibotec Pharm Ltd Derivados de pirimidina biciclicos inhibidores del vih.
MX2007009015A (es) 2005-01-27 2007-09-18 Tibotec Pharm Ltd Derivados de 2-(4-cianofenilamino)pirimidina que inhibien el virus de la inmunodeficiencia humana.
DK1858861T3 (da) 2005-03-04 2010-11-08 Tibotec Pharm Ltd HIV-inhiberende 2-(4-cyanophenyl)-6-hydroxylaminopyrimidiner
EP1912626B1 (fr) * 2005-08-08 2016-04-13 AbbVie Deutschland GmbH & Co KG Formes posologiques à biodisponibilité accrue
WO2007047253A2 (fr) * 2005-10-11 2007-04-26 Eastman Chemical Company Formulations pharmaceutiques de cyclodextrines et composes antifongiques de type azole
CA2630717C (fr) 2006-01-19 2015-02-24 Janssen Pharmaceutica N.V. Derives de pyridine et de pyrimidine en tant qu'inhibiteurs d'histone desacetylase
EP1832281A1 (fr) * 2006-03-10 2007-09-12 Abbott GmbH & Co. KG Procédé pour la production d'une dispersion solide d'un ingredient actif
WO2007113256A1 (fr) 2006-03-30 2007-10-11 Tibotec Pharmaceuticals Ltd. Pyrimidines substituées 5-(hydroxyméthylène et aminométhylène) inhibant le vih
CA2645958C (fr) 2006-03-30 2014-11-04 Tibotec Pharmaceuticals Ltd. Pyrimidines a substitution 5-amido inhibant le vih
KR20090094073A (ko) 2006-12-29 2009-09-03 티보텍 파마슈티칼즈 리미티드 Ｈｉｖ를 억제하는 6-치환된 피리미딘
CN106045965A (zh) 2006-12-29 2016-10-26 爱尔兰詹森科学公司 抑制hiv的5,6‑取代的嘧啶类化合物
US20110037185A1 (en) * 2008-04-30 2011-02-17 James Kowalski Continuous process for making pharmaceutical compositions
US9713575B2 (en) 2009-05-07 2017-07-25 Gea Process Engineering Limited Tablet production module and method for continuous production of tablets
US20120148678A1 (en) 2010-12-08 2012-06-14 Advanced Technologies And Regenerative Medicine, Llc. Sustained release of poorly water soluble active compounds
US10532102B2 (en) 2016-08-19 2020-01-14 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition and methods of uses
CN107441504A (zh) * 2017-09-06 2017-12-08 广州中医药大学 番茄红素包合物及其制备方法及番茄红素包合物片剂、胶囊和颗粒
CN110898015A (zh) * 2019-12-31 2020-03-24 上海汉维生物医药科技有限公司 一种伊曲康唑制剂的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61152765A (ja) * 1984-12-27 1986-07-11 Nippon Ekishiyou Kk シクロデキストリン類で包接された化合物を含有した合成樹脂製品及びその製造方法
US5009900A (en) * 1989-10-02 1991-04-23 Nabisco Brands, Inc. Glassy matrices containing volatile and/or labile components, and processes for preparation and use thereof
KR100291361B1 (ko) * 1992-10-14 2001-09-17 니뽄 신야쿠 가부시키가이샤 결정상태의전이방법
AU5376994A (en) * 1992-11-10 1994-06-08 Nippon Shinyaku Co. Ltd. Enclosure compound manufacturing method
FR2705677B1 (fr) * 1993-05-28 1995-08-11 Roquette Freres Micro-granules obtenus par extrusion-sphéronisation contenant une cyclodextrine.
EP0862463A1 (fr) * 1995-11-23 1998-09-09 Janssen Pharmaceutica N.V. Melanges solides de cyclodextrines prepares par fusion-extrusion
KR100331529B1 (ko) 1999-06-16 2002-04-06 민경윤 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법

Also Published As

Publication number Publication date
JP3310299B2 (ja) 2002-08-05
HUP9900730A2 (hu) 1999-07-28
NZ322907A (en) 1998-12-23
BR9611562A (pt) 1999-03-02
US6365188B1 (en) 2002-04-02
WO1997018839A1 (fr) 1997-05-29
PL189122B1 (pl) 2005-06-30
TR199800729T2 (xx) 1998-07-21
CZ154398A3 (cs) 1998-08-12
NO981078L (no) 1998-05-22
JPH11501050A (ja) 1999-01-26
ZA969831B (en) 1998-05-22
NO981078D0 (no) 1998-03-11
CN1198655C (zh) 2005-04-27
SK67298A3 (en) 1998-11-04
AU7694396A (en) 1997-06-11
PL326161A1 (en) 1998-08-31
AU725204B2 (en) 2000-10-05
EP0862463A1 (fr) 1998-09-09
IL123654A0 (en) 1998-10-30
HUP9900730A3 (en) 2001-04-28
CN1200677A (zh) 1998-12-02

Similar Documents

Publication Publication Date Title
AU725204B2 (en) Solid mixtures of cyclodextrins prepared via melt-extrusion
Giri et al. Cellulose and its derivatives for application in 3D printing of pharmaceuticals
Leuner et al. Improving drug solubility for oral delivery using solid dispersions
JP5022086B2 (ja) 医薬の剤形の使用方法
DE69222182T2 (de) Verfahren für die herstellung einer festen dispersion
EP2822539B1 (fr) Compositions de dispersions de solides nanocristallins
EP1845945B1 (fr) Procedé pour la préparation des formes de dosage comprenant une dispersion solide d'un agent active microcristalline
Singhal et al. Hot melt extrusion technique
WO2003043602A1 (fr) Dispersions solides contenant de la cyclodextrine substituee et un medicament insoluble et preparations afferentes
KR102065325B1 (ko) 셀룰로즈 에테르를 포함하는 용융-압출된 조성물
Shah et al. Melt extrusion in drug delivery: three decades of progress
Rajadhyax et al. Hot melt extrusion in engineering of drug cocrystals: a review
BR112018071722B1 (pt) Uso do amino açúcar como plastificante, composição em pó e seu processo de produção
KR100441109B1 (ko) 용융-압출하여제조된사이클로덱스트린의고체혼합물
US20240108639A1 (en) Compositions and methods of making cocrystals using dielectric heating with dispersive and distributive mixing
TR2021005753T (tr) Seli̇neksorun yeni̇ kati di̇spersi̇yonlari

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees